Sol-Gel Technologies Ltd. (SLGL)
NASDAQ: SLGL · Real-Time Price · USD
71.77
+1.43 (2.03%)
Oct 9, 2026, 4:00 PM EDT - Market closed
Sol-Gel Technologies Revenue
Sol-Gel Technologies had revenue of $591.00K in the quarter ending June 30, 2026, a decrease of -96.58%. This brings the company's revenue in the last twelve months to $1.80M, down -92.50% year-over-year. In the year 2025, Sol-Gel Technologies had annual revenue of $19.39M with 68.04% growth. That makes Sol-Gel Technologies the 42,590th largest company in the world by revenue and 5,831st in the United States.
Revenue (ttm)
$1.80M
Revenue Growth
-92.50%
P/S Ratio
130.91
Revenue / Employee
$64,107
Employees
28
Market Cap
234.97M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 19.39M | 7.85M | 68.04% |
| Dec 31, 2024 | 11.54M | 9.98M | 642.47% |
| Dec 31, 2023 | 1.55M | -2.33M | -59.98% |
| Dec 31, 2022 | 3.88M | -27.39M | -87.58% |
| Dec 31, 2021 | 31.27M | 22.50M | 256.54% |
| Dec 31, 2020 | 8.77M | -14.13M | -61.71% |
| Dec 31, 2019 | 22.90M | 22.78M | 17,655.04% |
| Dec 31, 2018 | 129.00K | -45.00K | -25.86% |
| Dec 31, 2017 | 174.00K | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| MacroGenics | 175.14M |
| Protalix BioTherapeutics | 80.62M |
| Sutro Biopharma | 45.70M |
| ProQR Therapeutics | 21.05M |
| Keros Therapeutics | 15.01M |
| Alector | 13.86M |
| Pyxis Oncology | 11.04M |
| Evommune | 10.00M |
SLGL News
- 11 days ago - Sol-Gel Technologies to Host KOL Investor Day for SGT-610 on October 14, 2026 - GlobeNewsWire
- 24 days ago - Sol-Gel Technologies announces last patient visit in SGT-610 trial - TheFly
- 24 days ago - Sol-Gel Technologies Announces Last Patient Last Visit in Pivotal Phase 3 Clinical Trial of SGT-610 in Gorlin Syndrome - GlobeNewsWire
- 7 weeks ago - Sol-Gel Technologies Earnings release: Q2 2026 - Filings
- 7 weeks ago - Sol-Gel Reports Second Quarter 2026 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 3 months ago - Sol-Gel Technologies initiated with an Outperform at Mizuho - TheFly
- 4 months ago - Sol-Gel Technologies initiated with a Buy at TD Cowen - TheFly
- 4 months ago - Sol-Gel Technologies reports Q1 EPS ($1.31) vs. ($3.20) last year - TheFly